Patents by Inventor Mikhail Krasavin

Mikhail Krasavin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250177412
    Abstract: Compounds of formula (I) or pharmaceutically acceptable salts and/or solvates thereof. Also, the use of the compounds of formula (I) as immunomodulators and in the treatment of autoimmune diseases, transplanted organ rejection, graft-versus-host-disease and BOB1-related diseases, in which the compounds of formula (I) are administered to subjects in need thereof.
    Type: Application
    Filed: March 22, 2023
    Publication date: June 5, 2025
    Applicants: NANTES UNIVERSITE, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), ACADEMISCH MEDISCH CENTRUM, FEDERAL STATE BUDGETARY INSTITUTION OF SCIENCE INSTITUTE OF CYTOLOGY OF THE RUSSIAN
    Inventors: Nataliya YEREMENKO, Sophie BROUARD, Alexey TOMILIN, Mikhail KRASAVIN, Maxim GUREEV
  • Patent number: 8420815
    Abstract: The present disclosure relates to novel compounds that can be used as anti-cancer agents in the prostate cancer therapy. In particular, the invention relates to N-acyl derivatives of 2,3-dihydro-1H-pyrrolo[2,3-b]quinolines having the structural Formula (I), stereoisomers, tautomers, racemics, prodrugs, metabolites thereof, or pharmaceutically acceptable salt and/or solvate thereof. The meaning of R1 is independently selected from H; C1-C6 Alkyl, cyclo-Alkyl or iso-Alkyl substituents; R2 is selected from C1-C6 Alkyl, cyclo-Alkyl or iso-Alkyl; substituted or non-substituted, fused or non-fused to substituted or non-substituted aromatic ring, aryl or heteroaryl groups. The invention also relates to methods for preparing said compounds, and to pharmaceutical compositions comprising said compounds.
    Type: Grant
    Filed: June 24, 2010
    Date of Patent: April 16, 2013
    Assignee: U.S. Department of Energy
    Inventors: Andrei A. Gakh, Mikhail Krasavin, Ruben Karapetian, Konstantin A. Rufanov, Igor Konstantinov, Elena Godovykh, Olga Soldatkina, Andrey V. Sosnov
  • Patent number: 8362047
    Abstract: The present disclosure relates to novel compounds that can be used as anti-cancer agents in the prostate cancer therapy. In particular, the invention relates N-substituted derivatives of 4-(hetero)aryl-1,2,5-oxadiazol-3-yl amines having the structural Formula (I) and (II), stereoisomers, tautomers, racemics, prodrugs, metabolites thereof, or pharmaceutically acceptable salt and/or solvate thereof. Meaning of R1 and R2 in the Formula (I) and (II) are defined in claim 1. The invention also relates to methods for preparing said compounds, and to pharmaceutical compositions comprising said compounds.
    Type: Grant
    Filed: June 24, 2010
    Date of Patent: January 29, 2013
    Assignee: U.S. Department of Energy
    Inventors: Andrei A. Gakh, Mikhail Krasavin, Ruben Karapetian, Konstantin A. Rufanov, Igor Konstantinov, Elena Godovykh, Olga Soldatkina, Andrey V. Sosnov
  • Patent number: 6136847
    Abstract: Biologically-active, water soluble, 3-substituted trioxanes of the formula ##STR1## wherein R represents a COOH-- substituted aryl group, a substituted or unsubstituted heteroaryl group or an alkyl group, and C.sub.12 -(p-carboxy)benzyloxy trioxanes of formula ##STR2## wherein R represents a substituted or unsubstituted alkyl, alkenyl, aryl or heteroaryl group and methods for their use as antiparasitic agents, particularly for the treatment of malaria.
    Type: Grant
    Filed: April 7, 1999
    Date of Patent: October 24, 2000
    Assignee: Johns Hopkins University
    Inventors: Gary H. Posner, Michael H. Parker, Mikhail Krasavin, Theresa A. Shapiro